Full Opinion

Case: 21-60762 Document: 353-1 Page: 1 Date Filed: 11/18/2026 United States Court of Appeals for the Fifth Circuit ____________ United States Court of Appeals Fifth Circuit FILED No. 21-60762 November 18, 2026 ____________ Thomas B. Plunkett, III Clerk SWT Global Supply, Incorporated, Petitioner, versus Food & Drug Administration, Respondent, consolidated with _____________ No. 21-60777 _____________ Cloud House, L.L.C., Petitioner, versus Food & Drug Administration, Respondent, consolidated with _____________ No. 21-60778 Case: 21-60762 Document: 353-1 Page: 2 Date Filed: 11/18/2026 _____________ Paradigm Distribution, Petitioner, versus Food & Drug Administration, Respondent, consolidated with _____________ No. 21-60779 _____________ Vaporized, Incorporated, Petitioner, versus Food & Drug Administration, Respondent, consolidated with _____________ No. 21-60801 _____________ SV Packaging, L.L.C., Petitioner, versus 2 Case: 21-60762 Document: 353-1 Page: 3 Date Filed: 11/18/2026 Food & Drug Administration, Respondent. ______________________________ Petitions from the Food & Drug Administration Agency Nos. PM0003792, PM0003640, PM0000968, PM0001094, PM0001168, PM0001191, PM0003578 ______________________________ Before Elrod, Chief Judge, and Wiener and Wilson, Circuit Judges. Per Curiam:* These consolidated petitions are among many recent regulatory disputes between the Food & Drug Administration (FDA) and e-cigarette manufacturers. FDA issued marketing denial orders (MDOs) to SWT Global Supply, Inc., Cloud House, L.L.C., Paradigm Distribution, Vaporized, Inc., and SV Packaging, L.L.C. (collectively, Petitioners). Petitioners then challenged the MDOs in this court. Based on our recent decisions in similar cases, we grant the petitions for review, vacate the MDOs, and remand to FDA for further proceedings. I. Petitioners initially sought review of the MDOs pertaining to their e-cigarette products several years ago. We consolidated the petitions and later granted them, following our decision in Wages & White Lion Invs., L.L.C. v. FDA, 90 F.4th 357 (5th Cir. 2024) (en banc). See SWT Glob. Supply, Inc. v. FDA, 2024 WL 3595387, at *2 (5th Cir. July 31, 2024). FDA then petitioned the Supreme Court for writs of certiorari in both Wages and these cases. The Court granted the petitions, vacated the underlying _____________________ * This opinion is not designated for publication. See 5th Cir. R. 47.5. 3 Case: 21-60762 Document: 353-1 Page: 4 Date Filed: 11/18/2026 21-60762 c/w Nos. 21-60777, 21-60778, 21-60779, 21-60801 judgments, and remanded the cases to our court for further proceedings. FDA v. Wages & White Lion Invs., L.L.C., 604 U.S. 542, 592 (2025); FDA v. SWT Glob. Supply, Inc., 145 S. Ct. 1919, 1919 (2025) (Mem.) (remanding for further consideration in light of Wages). After the cases were remanded, FDA agreed to consider the Petitioners’ proposed marketing plans. We granted the parties’ joint motion to hold the petitions in abeyance pending the agency’s review. Following its voluntary review, FDA maintained that the MDOs were appropriate. We then removed the petitions from abeyance, and the parties filed supplemental briefing addressing, inter alia, our recent cases addressing claims similar to those raised by Petitioners here. II. The Family Smoking Prevention and Tobacco Control Act (TCA) requires tobacco product manufacturers, including e-cigarette 1 manufacturers, to obtain FDA authorization before marketing their products. 21 U.S.C. § 387j(a)(2)(A). One way they may do so is by submitting premarket tobacco product applications to the agency. Id. § 387j(c)(1)(A)(i). In relevant part, the statute provides that FDA “shall deny” an application that fails to show that marketing the product would be “appropriate for the protection of the public health.” Id. § 387j(c)(2)(A). FDA has determined that non-tobacco-flavored e-cigarettes (e.g., fruit- and mint-flavored) are especially dangerous for minors because those e-cigarettes are more enticing than tobacco-flavored ones. VDX Distro, Inc. v. FDA, 179 F.4th 356, 360 (5th Cir. 2026). Therefore, FDA will not deem a non-tobacco-flavored e-cigarette “appropriate for the protection of the _____________________ 1 E-cigarette products count as “tobacco products” for purposes of the TCA. See Wages & White Lion Invs., LLC, 604 U.S. at 551. 4 Case: 21-60762 Document: 353-1 Page: 5 Date Filed: 11/18/2026 21-60762 c/w Nos. 21-60777, 21-60778, 21-60779, 21-60801 public health” unless it carries an advantage over tobacco-flavored e-cigarettes in helping adult cigarette smokers quit smoking or switch to e-cigarettes—a balancing test referred to as the “comparative-efficacy standard.” Id. at 362. Applying the comparative-efficacy standard, FDA denied Petitioners’ marketing applications for their non-tobacco-flavored e-cigarettes. Petitioners challenged those MDOs on various grounds in their initial petitions for review. But after years of intervening e-cigarette litigation, Petitioners press one argument: that FDA’s comparative-efficacy standard is a substantive rule adopted in violation of the Administrative Procedure Act’s (APA) notice-and-comment requirements for rulemaking. Our court recently addressed—and agreed with—this exact argument in NicQuid, LLC v. FDA, 188 F.4th 790 (5th Cir. 2026). As we explained, the FDA’s comparative-efficacy standard “constitutes a substantive rule.” Id. at 803. The APA thus required the agency to undertake notice-and-comment rulemaking before adopting the comparative-efficacy standard. Id. at 806. Because FDA failed to do so, we vacated the agency’s order denying the marketing application at issue. Id. at 809. As FDA concedes, NicQuid “control[s] the outcome here.” For the same reasons as articulated in NicQuid, these petitions for review are GRANTED, the MDOs are VACATED, and these matters are REMANDED to FDA for appropriate proceedings. 5